Bellicum Pharmacueticals Inc. (NASDAQ:BLCM)’s share price traded down 4.6% on Thursday . The stock traded as low as $15.55 and last traded at $15.62, with a volume of 194,223 shares changing hands. The stock had previously closed at $16.38.

Several equities analysts have weighed in on the company. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of Bellicum Pharmacueticals in a research report on Saturday, July 9th. Zacks Investment Research raised Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a research report on Monday, July 11th. Finally, SunTrust Banks Inc. assumed coverage on Bellicum Pharmacueticals in a research report on Thursday, June 2nd. They issued a “buy” rating and a $20.00 target price for the company. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $27.50.

The company has a 50-day moving average price of $13.55 and a 200 day moving average price of $11.23. The company’s market capitalization is $428.51 million.

Bellicum Pharmacueticals (NASDAQ:BLCM) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.07. On average, analysts predict that Bellicum Pharmacueticals Inc. will post ($2.22) EPS for the current year.

In related news, insider David M. Spencer sold 10,000 shares of the stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of $15.00, for a total transaction of $150,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Annemarie Moseley sold 25,000 shares of the stock in a transaction on Thursday, June 2nd. The shares were sold at an average price of $13.00, for a total value of $325,000.00. Following the sale, the chief operating officer now directly owns 18,486 shares in the company, valued at approximately $240,318. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Bellicum Pharmacueticals stock. Morgan Stanley increased its position in shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned 1.61% of Bellicum Pharmacueticals worth $8,653,000 as of its most recent SEC filing.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.